AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31694237 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (n = 17, 20 minutes of strength exercises at 50‐60% 1RM and 25 minutes of endurance training at 60‐80% HRmax)
Number of subjects: 39
Study 31694237 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (n = 22, 60‐80% HRmax)
Number of subjects: 39
Study 31694237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training programs
Number of subjects: 39
Study 28840615 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1 g/day)
Number of subjects: 120
Study 28840615 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipidated Curcumin (1 g/day, containing 200 mg of pure curcumin)
Number of subjects: 120
Study 28840615 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 g/day)
Number of subjects: 120
Study 26057939 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin supplementation (acute and chronic)
Number of subjects: 24
Study 26057939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23937271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg plus mirodenafil 50 mg (group B)
Number of subjects: 118
Study 23937271 — intervention group
Group type: COMPARATOR
Intervention: Dapoxetine 30 mg plus placebo (group A)
Number of subjects: 118
Study 21803422 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg linagliptin after an overnight fast of at least 10 hours
Number of subjects: 32
Study 21803422 — intervention group
Group type: COMPARATOR
Intervention: 5 mg linagliptin after ingestion of a high-fat, high-calorie breakfast
Number of subjects: 32
Study 19781210 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/qn)
Number of subjects: 120
Study 19781210 — intervention group
Group type: COMPARATOR
Intervention: Control (no atorvastatin)
Number of subjects: 120
Study 16487269 — intervention group
Group type: EXPERIMENTAL
Intervention: GNB3 C825T polymorphism
Number of subjects: 1568
Study 16487269 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of the T allele in obese population
Number of subjects: 1568
Study 15462686 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 252
Study 15462686 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 100 mg
Number of subjects: 252
Study 15462686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 11562389 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-induced fluorescence endoscopy (LIFE)
Number of subjects: 55
Study 11562389 — intervention group
Group type: COMPARATOR
Intervention: Conventional white-light bronchoscopy (WLB)
Number of subjects: 55
Study 11562389 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined LIFE and WLB
Number of subjects: 55
Study 9576201 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha2b-IFN (Intron-A) maintenance therapy
Number of subjects: 284
Study 9576201 — intervention group
Group type: COMPARATOR
Intervention: no maintenance therapy
Number of subjects: 284
Study 7936018 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 16
Study 7936018 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 16
Study 7936018 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of azathioprine
Number of subjects: 16
Study 2953770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (1.25 mg/kg body weight over 3 hours)
Number of subjects: 100
Study 2953770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2953770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator
Number of subjects: 100
Study 2953770 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary streptokinase/placebo
Number of subjects: 100
Study 2953770 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary streptokinase
Number of subjects: 100
Study 2953770 — intervention group
Group type: COMPARATOR
Intervention: Placebo/intracoronary streptokinase
Number of subjects: 100
Study 29607480 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 143
Study 29607480 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 143
Study 29607480 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 143
Study 26886406 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care augmented by virtual house calls with a Parkinson's disease specialist (4 virtual visits over 1 year via secure, Web‐based videoconferencing)
Number of subjects: 210
Study 26886406 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 210
Study 24771805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 44
Study 24771805 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride)
Number of subjects: 44
Study 23512329 — intervention group
Group type: EXPERIMENTAL
Intervention: p114RhoGEF expression in squamous-cell lung carcinoma
Number of subjects: 105
Study 23512329 — intervention group
Group type: EXPERIMENTAL
Intervention: p114RhoGEF expression
Number of subjects: 105
Study 20932130 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser therapy (2,940 nm, 60 mJ/pulse, 2 Hz, 20 s)
Number of subjects: 24
Study 20932130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser therapy (1,064 nm, 100 mJ/pulse, 15 Hz, 100 s)
Number of subjects: 24
Study 20932130 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser therapy (808 nm, 100 mW, 20s)
Number of subjects: 24
Study 20932130 — intervention group
Group type: COMPARATOR
Intervention: Control group (not irradiated)
Number of subjects: 24
Study 18379555 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume peritoneal dialysis (HVPD)
Number of subjects: 120
Study 18379555 — intervention group
Group type: COMPARATOR
Intervention: Daily hemodialysis (DHD)
Number of subjects: 120
Study 12271300 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 3 times per week for 8 weeks
Number of subjects: 22
Study 12271300 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream applied to the other side of the body
Number of subjects: 22
Study 9649912 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10-40 mg o.d. after 3 and 12 months
Number of subjects: 25
Study 9649912 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide monotherapy
Number of subjects: 25
Study 9649912 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive subjects)
Number of subjects: 25
Study 9649912 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients during exercise
Number of subjects: 25
Study 7530029 — intervention group
Group type: EXPERIMENTAL
Intervention: bovine heparin 300 u. kg‐1 (standard)
Number of subjects: 60
Study 7530029 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin 300 u. kg‐1 followed by a continuous infusion of 10,000 u. kg‐1 until the end of CPB
Number of subjects: 60
Study 7530029 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin 600 u. kg‐1
Number of subjects: 60
Study 7530029 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin 600 u. kg‐1 in addition to high‐dose aprotinin 2 million iu before CPB, 500,000 iu h‐1 until the end of operation and 2 million iu added to the prime
Number of subjects: 60
Study 7530029 — intervention group
Group type: COMPARATOR
Intervention: saline solution (control)
Number of subjects: 60
Study 2586435 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral OK-432
Number of subjects: 1011
Study 2586435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1011
Study 2586435 — intervention group
Group type: COMPARATOR
Intervention: Intravenous OK-432
Number of subjects: 1011
Study 781905 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan (mean dosage of 464 mg over 301 days)
Number of subjects: 588
Study 781905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 588
Study 781905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 28146393 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFL reconstruction in addition to TTT and LR
Number of subjects: 34
Study 28146393 — intervention group
Group type: COMPARATOR
Intervention: Control group (lateral release and TTT)
Number of subjects: 34
Study 25030898 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rTMS and LLLT
Number of subjects: 30
Study 25030898 — intervention group
Group type: COMPARATOR
Intervention: rTMS
Number of subjects: 30
Study 25030898 — intervention group
Group type: COMPARATOR
Intervention: LLLT
Number of subjects: 30
Study 23556337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg
Number of subjects: 12
Study 23556337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg
Number of subjects: 12
Study 23556337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 12
Study 23556337 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-G carriers of ABCB1 G2677T/A
Number of subjects: 12
Study 23556337 — intervention group
Group type: EXPERIMENTAL
Intervention: SLCO1B1*17 carriers
Number of subjects: 12
Study 23556337 — intervention group
Group type: EXPERIMENTAL
Intervention: Female SLCO1B1 521TT subjects
Number of subjects: 12
Study 23556337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 12
Study 21813728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy cessation for 1 month or 2 months before the next screening mammogram
Number of subjects: 1168
Study 21813728 — intervention group
Group type: COMPARATOR
Intervention: Continuation of hormone therapy
Number of subjects: 1168
Study 19918152 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognitive theory-based structured hip fracture prevention website (TSW) with learning modules and a moderated discussion board for 2 weeks
Number of subjects: 90
Study 16444660 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg dose of Melissa officinalis and Valeriana officinalis
Number of subjects: 24
Study 16444660 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg dose of Melissa officinalis and Valeriana officinalis
Number of subjects: 24
Study 16444660 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg, 1200 mg, and 1800 mg doses of Melissa officinalis and Valeriana officinalis
Number of subjects: 24
Study 16444660 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg and 1200 mg doses of Melissa officinalis and Valeriana officinalis
Number of subjects: 24
Study 16444660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14992980 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Number of subjects: 978
Study 14992980 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 978
Study 14992980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 978
Study 14992980 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (8, 16, or 24 mg/day)
Number of subjects: 978
Study 11434897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg bid
Number of subjects: 2702
Study 11434897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg bid
Number of subjects: 2702
Study 11434897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2702
Study 11434897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 2702
Study 11434897 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 2702
Study 9374712 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 40
Study 9374712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 9374712 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40
Study 9374712 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 40
Study 9374712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 40
Study 8498732 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator treatment
Number of subjects: 58
Study 30289174 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive decision tool (iCanDecide)
Number of subjects: 537
Study 30289174 — intervention group
Group type: COMPARATOR
Intervention: Control group (static website)
Number of subjects: 537
Study 27695851 — intervention group
Group type: EXPERIMENTAL
Intervention: ParentCorps-enhanced prekindergarten programs
Number of subjects: 1050
Study 24630869 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-rEPA conjugate vaccine
Number of subjects: 0
Study 22506886 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional simulation program
Number of subjects: 84
Study 20420639 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC/MMF/DAC
Number of subjects: 196
Study 20420639 — intervention group
Group type: COMPARATOR
Intervention: TAC/MMF/STR
Number of subjects: 196
Study 18824016 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion-defined contours in peripheral vision with drifting dots and static dot patterns.
Number of subjects: 0
Study 18824016 — intervention group
Group type: COMPARATOR
Intervention: Uniform dark area substituted for static dots.
Number of subjects: 0
Study 18824016 — intervention group
Group type: EXPERIMENTAL
Intervention: Two fields of dots moving in opposite directions.
Number of subjects: 0
Study 18824016 — intervention group
Group type: EXPERIMENTAL
Intervention: Varying the velocity of the more eccentric region.
Number of subjects: 0
Study 18824016 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminability of contours in diverging and converging patterns.
Number of subjects: 0
Study 16490583 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clindamycin 300 mg BID
Number of subjects: 774
Study 16490583 — intervention group
Group type: COMPARATOR
Intervention: Oral amoxicillin/clavulanic acid 1 g BID
Number of subjects: 774
Study 14672477 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the Pelvic Organ Prolapse Incontinence Sexual Questionnaire (PISQ)
Number of subjects: 26
Study 14672477 — intervention group
Group type: COMPARATOR
Intervention: English version of the Pelvic Organ Prolapse Incontinence Sexual Questionnaire (PISQ)
Number of subjects: 26
Study 10623706 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (200 mg/m²/d for 5 days every 28 days)
Number of subjects: 305
Study 10623706 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) (250 mg/m²/d for 5 days every 21 days)
Number of subjects: 305
Study 10623706 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 305
Study 10623706 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC)
Number of subjects: 305
Study 9180443 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 39
Study 9180443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 39
Study 8250314 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 1 mg
Number of subjects: 32
Study 8250314 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 3 mg
Number of subjects: 32
Study 8250314 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 10 mg
Number of subjects: 32
Study 8250314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8250314 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 32
Study 3814226 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg ketanserin
Number of subjects: 7
Study 3814226 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg clonidine
Number of subjects: 7
Study 3814226 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml saline)
Number of subjects: 7
Study 30972696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (0.125-2.25 mg/kg)
Number of subjects: 45
Study 29986688 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Health Intervention for Development Outcomes (CHIDO) intervention
Number of subjects: 30
Study 29986688 — intervention group
Group type: COMPARATOR
Intervention: Ministry of Health standard care
Number of subjects: 30
Study 27022112 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 561
Study 27022112 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 561
Study 25233931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine metabolism by cytochrome P450 2A6‐catalyzed C‐oxidation
Number of subjects: 1839
Study 25233931 — intervention group
Group type: EXPERIMENTAL
Intervention: UDP‐glucuronosyl transferase 2B10 (UGT2B10)‐catalyzed N‐glucuronidation
Number of subjects: 1839
Study 25233931 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT2B10 genotype variants (Asp67Tyr, rs61750900 and rs116294140)
Number of subjects: 1839
Study 25233931 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT2B10 variant allele carriers
Number of subjects: 1839
Study 22292153 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate provisionalization with nonocclusal loading (Group A)
Number of subjects: 117
Study 22292153 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate provisionalization with occlusal loading (Group B)
Number of subjects: 117
Study 22292153 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed loading with single-stage surgery (Group C)
Number of subjects: 117
Study 20816146 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (17P) 250 mg weekly injections
Number of subjects: 81
Study 20816146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 20816146 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (17P)
Number of subjects: 81
Study 17885721 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-germinated brown rice
Number of subjects: 41
Study 17885721 — intervention group
Group type: COMPARATOR
Intervention: White rice (control)
Number of subjects: 41
Study 16253149 — intervention group
Group type: EXPERIMENTAL
Intervention: Rib-cage compression before endotracheal suctioning
Number of subjects: 31
Study 16253149 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal suctioning without rib-cage compression
Number of subjects: 31
Study 12374435 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental aggression (facilitated by personal rewards)
Number of subjects: 0
Study 12374435 — intervention group
Group type: COMPARATOR
Intervention: Reactive aggression (facilitated by situational provocation)
Number of subjects: 0
Study 10440559 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for detecting selection bias based on response data only.
Number of subjects: 0
Study 10440559 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparisons across treatment groups.
Number of subjects: 0
Study 7751077 — intervention group
Group type: EXPERIMENTAL
Intervention: Braked jumps using the Plyometric Power System (PPS) with braking mechanism set at 75% of body weight during the downward phase.
Number of subjects: 20
Study 7751077 — intervention group
Group type: COMPARATOR
Intervention: Non-braked jumps (control condition).
Number of subjects: 20
Study 1983724 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam, 1.5 mg/day
Number of subjects: 100
Study 400194 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI) and Chemotherapy (CVP)
Number of subjects: 21
Study 400194 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CVP)
Number of subjects: 21
Study 400194 — intervention group
Group type: COMPARATOR
Intervention: Total Body Irradiation (TBI)
Number of subjects: 21
Study 400194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TBI and CVP
Number of subjects: 21
Study 30576268 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus prednisone (DP) or a DP-containing regimen
Number of subjects: 8820
Study 28124802 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent consumption of Caspian white fish marinated in essential oil of Perilla frutescens (EOPF), 434 g each week or four meals per week.
Number of subjects: 180
Study 28124802 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent consumption of Caspian white fish without EOPF, 434 g each week or four meals per week.
Number of subjects: 180
Study 28124802 — intervention group
Group type: COMPARATOR
Intervention: Common diet (control group).
Number of subjects: 180
Study 26229455 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal alcohol intake (<1 drink/month)
Number of subjects: 1082
Study 26229455 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-to-moderate alcohol intake (1-60 drinks/month)
Number of subjects: 1082
Study 26229455 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy alcohol intake (>60 drinks/month)
Number of subjects: 1082
Study 21200007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID (D110)
Number of subjects: 1270
Study 21200007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID (D150)
Number of subjects: 1270
Study 21200007 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1270
Study 19620877 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg once daily
Number of subjects: 25
Study 19620877 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg twice daily
Number of subjects: 25
Study 19620877 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 25
Study 17065182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention at a heart failure clinic by a clinician and a cardiovascular nurse, including 9 scheduled patient contacts over 1 year, comprehensive education, treatment optimisation, and self-care advice.
Number of subjects: 240
Study 17065182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention at a heart failure clinic
Number of subjects: 240
Study 17065182 — intervention group
Group type: COMPARATOR
Intervention: Usual care (outpatient visits by individual cardiologists following European Society of Cardiology guidelines)
Number of subjects: 240
Study 12868997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/d
Number of subjects: 72
Study 12868997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72